Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Abasaglar Summary of Product Characteristics (SmPC)

Is Abasaglar® (insulin glargine) safe to use while breastfeeding?

There are no data on the presence of Abasaglar in breast milk nor on its effects on the breastfed infant.

UK_cFAQ_BIV071_USE_BREASTFEEDING
cFAQ
cFAQ
UK_cFAQ_BIV071_USE_BREASTFEEDING
en-GB

Abasaglar Use While Breast-Feeding

It is unknown whether insulin glargine is excreted in human milk.1

No metabolic effects of ingested insulin glargine on the breast-fed newborn or infant are anticipated since insulin glargine, as a peptide, is digested into amino acids in the human gastrointestinal tract.1

Breast-feeding women may require adjustments in insulin dose and diet.1

References

1Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Date of Last Review: April 06, 2021


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request